- Home
- WLY vs DNLI Comparison
WLY vs DNLI Comparison
Compare WLY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- DNLI
- Stock Information
- Founded
- WLY 1807
- DNLI 2013
- Country
- WLY United States
- DNLI United States
- Employees
- WLY N/A
- DNLI N/A
- Industry
- WLY Books
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLY Consumer Discretionary
- DNLI Health Care
- Exchange
- WLY Nasdaq
- DNLI Nasdaq
- Market Cap
- WLY 2.1B
- DNLI 2.1B
- IPO Year
- WLY N/A
- DNLI 2017
- Fundamental
- Price
- WLY $39.21
- DNLI $13.92
- Analyst Decision
- WLY
- DNLI Strong Buy
- Analyst Count
- WLY 0
- DNLI 15
- Target Price
- WLY N/A
- DNLI $33.85
- AVG Volume (30 Days)
- WLY 587.9K
- DNLI 1.5M
- Earning Date
- WLY 09-04-2025
- DNLI 08-04-2025
- Dividend Yield
- WLY 3.58%
- DNLI N/A
- EPS Growth
- WLY N/A
- DNLI N/A
- EPS
- WLY 1.53
- DNLI N/A
- Revenue
- WLY $1,677,609,000.00
- DNLI N/A
- Revenue This Year
- WLY $1.45
- DNLI N/A
- Revenue Next Year
- WLY $2.70
- DNLI $323.34
- P/E Ratio
- WLY $25.78
- DNLI N/A
- Revenue Growth
- WLY N/A
- DNLI N/A
- 52 Week Low
- WLY $36.50
- DNLI $10.57
- 52 Week High
- WLY $53.96
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- WLY 37.39
- DNLI 45.66
- Support Level
- WLY $39.13
- DNLI $13.70
- Resistance Level
- WLY $40.36
- DNLI $14.60
- Average True Range (ATR)
- WLY 0.87
- DNLI 0.65
- MACD
- WLY -0.35
- DNLI -0.06
- Stochastic Oscillator
- WLY 1.65
- DNLI 13.13
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.